Compare SFNC & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SFNC | NUVB |
|---|---|---|
| Founded | 1903 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.9B |
| IPO Year | N/A | N/A |
| Metric | SFNC | NUVB |
|---|---|---|
| Price | $19.28 | $9.47 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $22.75 | $10.63 |
| AVG Volume (30 Days) | 1.1M | ★ 6.8M |
| Earning Date | 01-20-2026 | 11-03-2025 |
| Dividend Yield | ★ 4.41% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $26,748,000.00 |
| Revenue This Year | $27.12 | $609.55 |
| Revenue Next Year | $7.58 | $197.91 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 1137.19 |
| 52 Week Low | $17.00 | $1.54 |
| 52 Week High | $23.44 | $9.53 |
| Indicator | SFNC | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 56.93 | 74.81 |
| Support Level | $19.01 | $8.13 |
| Resistance Level | $19.83 | $8.95 |
| Average True Range (ATR) | 0.41 | 0.54 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 52.86 | 96.87 |
Simmons First National Corp is a financial holding company. The company through its subsidiaries is engaged in providing banking services including consumer, real estate and commercial loans, checking, savings and time deposits. The company's loan portfolio comprises construction, single-family residential and commercial loans; non-real estate loans, nonaccrual and past due loans; and credit card loans, student loans and other consumer loans. It also offers various products and services such as trust services, investments, agricultural finance lending, equipment lending, insurance, consumer finance and small business administration lending. The business activity of the firm is functioned through the region of the United States.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.